Annuncio • May 02
Hyperion DeFi, Inc. to Report Q1, 2026 Results on May 14, 2026 Hyperion DeFi, Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026 Annuncio • Apr 21
Hyperion DeFi, Inc., Annual General Meeting, Jun 30, 2026 Hyperion DeFi, Inc., Annual General Meeting, Jun 30, 2026. Annuncio • Mar 17
Hyperion DeFi, Inc. to Report Q4, 2025 Results on Mar 26, 2026 Hyperion DeFi, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 26, 2026 Annuncio • Feb 06
Hyperion Defi, Inc. Announces Institutional Volatility Income Vault Built on Rysk Protocol Hyperion DeFi, Inc. announced that it has engaged with the Rysk protocol ("Rysk") to launch a new institutional-grade, on-chain yield-enhancement vault native to the HyperEVM. Through this vault, Hyperion DeFi and its institutional partners will be able to utilize HYPE Liquid Staking tokens (LSTs) and stablecoins as collateral for on-chain options strategies, generating additional yield beyond staking income. Hyperion DeFi will initially deploy the vault for its own balance sheet before selectively opening access to other qualified participants. Participants will be gated through HiHYPE (Hyperion Institutional HYPE), which is minted exclusively by staking staking HYPE to the 'Kinetiq x Hyperion' validator. This structure is designed to create a controlled, institutional-only access model while driving incremental, diversified fee revenue to Hyperion DeFi over time. This new partnership further accelerates the Company's DeFi flywheel, scaling income streams while continuing to position the Company for ecosystem rewards. As of January 2026, more than 37 million HYPE have been autonomously purchased and sequestered by the blockchain with the trading fees generated on the network's central limit order books. Annuncio • Nov 17
Hyperion DeFi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Hyperion DeFi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Annuncio • Nov 16
Hyperion Defi, Inc. Reports Unaudited Impairment Charges for the Third Quarter Ended September 30, 2025 Hyperion DeFi, Inc. reported unaudited impairment charges for the third quarter ended September 30, 2025. For the quarter, the company reported Impairment loss - digital intangible assets of $6,289,847. Annuncio • Nov 04
Hyperion DeFi, Inc. to Report Q3, 2025 Results on Nov 13, 2025 Hyperion DeFi, Inc. announced that they will report Q3, 2025 results on Nov 13, 2025 Annuncio • Sep 30
Hyperion Defi, Inc. Announces Appointment of David Knox as Chief Financial Officer, Effective September 29, 2025 Hyperion DeFi, Inc. announced the appointment of David Knox, CFA, as Chief Financial Officer, effective September 29, 2025. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company’s decentralized finance (“DeFi”) strategy. Mr. Knox brings with him extensive expertise in scaling capital markets strategies and financial services businesses. He joins Hyperion DeFi from PayPal, where he served as Head of Capital Markets and Head of Finance for Global Credit and Financial Services. In his dual role at PayPal, he led the profitable expansion of the company’s lending segments under a “balance sheet light” strategic imperative and managed core FP&A responsibilities with rigorous governance and reporting across the PayPal and Venmo global financial services platforms. Earlier in his career, Mr. Knox was Director at Cantor Fitzgerald, where he provided capital markets structuring and advisory services across mortgage-backed and asset-backed finance transactions. He also held prior roles in lending and capital markets at SoFi, Hudson Advisors, and the Royal Bank of Scotland. Mr. Knox holds a bachelor’s degree from the University of Connecticut and is an alumnus of the Harvard Business School. Annuncio • Sep 09
Hyperion DeFi, Inc. Regains Compliance with Nasdaq Listing Requirements As previously reported, on April 29, 2025, Hyperion DeFi, Inc. received a notice from the staff of the Nasdaq Stock Market LLC stating that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 was below the minimum $2,500,000 required for continued listing under Listing Rule 5550(b)(1). On September 2, 2025, the Company received a notice from the Staff indicating that the Company has regained compliance with the Minimum Equity Requirement. Annuncio • Jul 14
Hyperion DeFi, Inc., Annual General Meeting, Aug 18, 2025 Hyperion DeFi, Inc., Annual General Meeting, Aug 18, 2025. Annuncio • Jun 24
Eyenovia, Inc. announced that it has received $50 million in funding On June 23, 2025, Eyenovia, Inc. closed the transaction. Annuncio • Jun 19
Eyenovia, Inc. announced that it expects to receive $50 million in funding Eyenovia, Inc announced a private placement to issue non-voting convertible preferred stock and warrants for gross proceeds $50,000,000 on June 18, 2025. The financing potentially raising up to $150,000,000 in total proceeds if the warrants are exercised. The Company will issue non-voting convertible preferred stock convertible into approximately 15,400,000 shares of the Company’s common stock at a conversion price of $3.25 per share, and warrants to purchase approximately 30,800,000 shares of the Company’s common stock, at an exercise price of $3.25 per share. The conversion of the preferred stock and the exercise of the warrants are subject to beneficial ownership limitations set by the investors. The closing of the offering is expected to occur on or about June 20, 2025, subject to the satisfaction of customary closing conditions Annuncio • May 16
Eyenovia, Inc. announced delayed 10-Q filing On 05/15/2025, Eyenovia, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • May 03
Eyenovia Receives A Notice from the Staff of the Nasdaq Stock Market Regarding Minimum Equity Requirement On April 29, 2025, Eyenovia, Inc. (the “Company”) received a notice (the “Notice”) from the staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 was below the minimum $2,500,000 required for continued listing under Listing Rule 5550(b)(1) (the “Minimum Equity Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market, which continues to trade under the symbol “EYEN”. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until June 13, 2025, to submit a plan to regain compliance with the Minimum Equity Requirement. The Company intends to submit a plan to regain compliance with the Nasdaq Listing Rules. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to regain compliance, or until October 26, 2025. If the Staff does not accept our plan, we will have the opportunity to appeal that decision to a Hearings Panel. Annuncio • Apr 10
Eyenovia, Inc. Provides Development Update on Optejet User Filled Device (UFD) Eyenovia, Inc. provided an update on recent progress made in the development of the Company's novel Optejet UFD. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. Eyenovia continues to advance the Optejet UFD through Verification & Validation (V&V) studies to ensure that the device meets the standards around intended use and customer requirements. As of April 10, 2025, the Company has completed the following parameters: Physical requirements such as dimensions and weight, and presence and operation of various light indicators. Usability requirements identified, including forces required to actuate the device or connect and disconnect the cartridge. Dosing performance, with consistency in delivering ophthalmic liquids to within a standard deviation of 1 microliter. This testing includes, among other things, electromagnetic interference, compatibility, and electrostatic discharge testing. The Optejet UFD has satisfactorily met all requirements. Annuncio • Apr 01
Eyenovia, Inc. announced delayed annual 10-K filing On 03/31/2025, Eyenovia, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Mar 21
Betaliq, Inc. entered into a non-binding letter of intent to acquire Eyenovia, Inc. (NasdaqCM:EYEN) in a reverse merger transaction. Betaliq, Inc. entered into a non-binding letter of intent to acquire Eyenovia, Inc. (NasdaqCM:EYEN) in a reverse merger transaction on March 18, 2025. The proposed transaction assumes a value for Betaliq of approximately $77 million and a value for Eyenovia of approximately $15 million, assuming zero cash (net of liabilities) at merger closing. The exchange ratio is intended to result in Betaliq equity holders owning approximately 83.7% of the combined company, while Eyenovia equity holders would own approximately 16.3% at the closing of the merger, on a fully diluted basis.
The proposed transaction remains subject to completion of mutually satisfactory due diligence, the negotiation and execution of definitive agreements on mutually satisfactory terms, the approval of such definitive documentation by the boards of directors of both Eyenovia and Betaliq, and the completion of necessary financing contingencies. Chardan Capital Markets, LLC is acting as financial advisor to Eyenovia in connection with the proposed transaction. Raymond James is acting as financial advisor to Betaliq. Annuncio • Feb 26
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements Eyenovia, Inc. announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule. “Maintaining our Nasdaq listing, along with other steps we have taken to restructure the company and accelerate development of the user-filled Optejet, represent important milestones as we continue to evaluate a broad range of strategic alternatives and maximize shareholder value,” stated Michael Rowe, Chief Executive Officer. “We are grateful to our shareholders who approved of our recent decision to effect a reverse stock split that made it possible for us to regain compliance with the Nasdaq continued listing requirements”. Annuncio • Feb 05
Eyenovia, Inc. Announces Progress on Next-Generation User-Filled Optejet Dispensing Device Eyenovia, Inc. announced recent progress on the development of its user-filled spray dispenser. Some of the features incorporated into the user-filled Optejet include: User-Filled Cartridge: The new design includes a sterile disposable cartridge that users can fill using their own, fresh eyedropper bottle. The cartridge is then attached to the reusable base unit and would be capable of dispensing up to 180 metered sprays. Once empty, the cartridge is simply replaced with a new user-filled cartridge. Reliable and Precise Spray: rigorous testing has resulted in observations of the Optejet's durable base unit performing over 30,000 sprays, and 98% of the Optejet sprays were between 8-9 microliters (approximately equal to the amount of liquid the eye can hold) over 180 doses, meeting exacting specifications. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, such as artificial tears and lens rewetting products, which are expected to generate sales of four billion dollars in the U.S. this year alone. Annuncio • Jan 29
Eyenovia Announces 1-for-80 Reverse Stock Split to Regain Compliance with Bid Price Requirement Eyenovia, Inc. announced that its Board of Directors approved a 1-for-80 reverse stock split (the “Reverse Stock Split”) of its outstanding shares of common stock, $0.0001 par value per share, which is within the ratio range approved by the Company’s stockholders at a special meeting of stockholders held on January 21, 2025. The Reverse Stock Split will be effective at 4:00 p.m., Eastern Time, on January 31, 2025. At the market open on February 3, 2025, the common stock will begin trading on a post-split basis under the existing ticker symbol “EYEN” and new CUSIP number 30234E 203. The Reverse Stock Split is being effected to enable the Company to regain compliance with the minimum bid price required to remain listed on the Nasdaq Capital Market. Annuncio • Dec 31
Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $33.586557 million. Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $33.586557 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Annuncio • Dec 15
Nasdaq Determines to Delist Eyenovia's Securities As previously disclosed, on September 18, 2024, Eyenovia, Inc. (the Company") received a letter from the staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") providing notification that, for the previous 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until March 17, 2025, to regain compliance with this requirement (the Bid Price Cure Period"). On December 12, 2024, the Company received a letter from Nasdaq notifying the Company that, as of December 11, 2024, the common stock had a closing bid price of $0.10 or less for 10 consecutive trading days. Accordingly, the Company is subject to the provisions of Listing Rule 5810(c)(3)(A)(iii) (the Low Priced Stocks Rule"). As a result, Nasdaq has determined to delist the Company's securities from The Nasdaq Capital Market, notwithstanding the Bid Price Cure Period, which is rendered unavailable by the Low Priced Stocks Rule. The Company has the right to appeal Nasdaq's determination by December 19, 2024, and it intends to appeal such determination before a panel (the Hearings Panel"). The hearing request will stay the suspension of the trading of the Company's common stock pending the decision of the Hearings Panel. At such hearing, the Company intends to submit its plan to regain compliance with the applicable Nasdaq listing rules discussed above. On December 12, 2024, the Company filed a preliminary proxy statement for a Special Meeting of Stockholders to be held on January 21, 2025 to consider certain proposals, including approval of a reverse stock split, which is intended to result in an increase in the trading price of the Company's common stock that would cure the listing deficiencies noted above. No assurances can be provided that the Company will obtain a favorable decision from the Hearings Panel, and/or that the Company will be able to regain or maintain compliance with Nasdaq's listing rules. Annuncio • Nov 26
Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million. Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 12,081,785
Price\Range: $0.1076
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 24,163,570
Transaction Features: Registered Direct Offering New Risk • Nov 18
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$38m Forecast net loss in 3 years: US$15m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Revenue is less than US$1m (US$32k revenue). Market cap is less than US$10m (US$8.80m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). New Risk • Nov 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$8.80m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Revenue is less than US$1m (US$32k revenue). Market cap is less than US$10m (US$8.80m market cap). Annuncio • Nov 16
Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study Eyenovia, Inc. announced that a review of the CHAPERONE data by an independent Data Review Committee (DRC) found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in visual acuity over three years. CHAPERONE is Eyenovia's Phase 3 study evaluating its proprietary drug-device combination of low-dose atropine in the Company's Optejet dispensing platform as a potential treatment for pediatric progressive myopia. The DRC reviewed the safety and efficacy data from 252 evaluable patients. The DRC found that the rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo. In the safety analysis, all dosages and placebo appeared to be well-tolerated, with a mild and infrequent adverse event profile. Full study data has not yet been released to Eyenovia. In light of the results of this review, the Company is considering a variety of steps to maximize value to all stakeholders, to reduce expenses and to evaluate its strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives. Further information will be made available once the evaluation of strategic options has been completed. Annuncio • Nov 07
Eyenovia, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Eyenovia, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 Annuncio • Oct 16
Eyenovia, Inc. Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo Eyenovia, Inc. announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, which is being held October 19-21, in Chicago. The presentation will detail the results of a successful Phase 3 study (CPN-302) of clobetasol propionate suspension 0.05% (APP13007) that led to its approval by the U.S. Food and Drug Administration as a treatment for inflammation and pain following ocular surgery. Eyenovia announced the U.S. launch and commercial availability of clobetasol on September 26, 2024. Annuncio • Oct 02
Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million. Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Annuncio • Sep 27
Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million. Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 8,695,653
Price\Range: $0.46
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 8,695,653
Transaction Features: Registered Direct Offering Annuncio • Sep 21
Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement On September 18, 2024, Eyenovia, Inc. (the Company") received a letter from the staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") providing notification that, for the previous 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Nasdaq's notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market, which continues to trade under the symbol EYEN". In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 17, 2025, to regain compliance with this requirement. To regain compliance, the closing bid price of the Company's common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before March 17, 2025. If the Company does not regain compliance with Rule 5550(a)(2) by March 17, 2025, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other Nasdaq initial listing standards, except the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities will be subject to delisting. In the event of such notification, the Company may appeal the Staff's determination to delist its securities, but there can be no assurance the Staff would grant the Company's request for continued listing. The Company intends to actively monitor the minimum bid price of its common stock and may, as appropriate, consider available options to regain compliance. Annuncio • Sep 03
Eyenovia, Inc. Announces Chief Financial Officer Changes Eyenovia, Inc. announced the appointment of Andrew Jones as chief financial officer. Mr. Jones brings to the company team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as Chief Financial Officer of NovaBay Pharmaceuticals, Inc. Eyenovia’s current CFO, John Gandolfo, is retiring and will remain with the company through November to help ensure a smooth transition. Prior to joining Eyenovia, Mr. Jones served as the Chief Financial Officer and Treasurer of NovaBay Pharmaceuticals during a successful period of commercial growth and cost reductions. Prior to joining NovaBay, he served as Vice President of Finance at MyoScience, Inc. Mr. Jones previously served as Controller for various public and private life sciences companies including Armetheon, Inc., Asante Solutions, Inc. and Genelabs Technologies, Inc., and began his career with PricewaterhouseCoopers. Mr. Jones received a B.S. degree in Business Administration from the University of Washington in Seattle. Annuncio • Aug 24
Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million. Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 12,850,000
Price\Range: $0.4
Discount Per Security: $0.028
Transaction Features: Registered Direct Offering Annuncio • Aug 21
Eyenovia, Inc. has filed a Follow-on Equity Offering. Eyenovia, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Warrants
Security Type: Equity Warrant
Transaction Features: Registered Direct Offering New Risk • Aug 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$30m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$30m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$2.4m). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Revenue is less than US$1m (US$31k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Market cap is less than US$100m (US$48.4m market cap). Major Estimate Revision • Aug 14
Consensus revenue estimates decrease by 47% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$3.54m to US$1.86m. EPS estimate increased from -US$0.677 to -US$0.67 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.9% next year. Consensus price target down from US$9.00 to US$8.33. Share price fell 19% to US$0.76 over the past week. Price Target Changed • Aug 13
Price target decreased by 11% to US$8.33 Down from US$9.33, the current price target is an average from 3 analysts. New target price is 944% above last closing price of US$0.80. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$0.66 last year. Annuncio • Aug 08
Eyenovia, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Eyenovia, Inc. announced that they will report Q2, 2024 results After-Market on Aug 12, 2024 Annuncio • Jul 06
Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2) On July 2, 2024, Eyenovia, Inc. (‘the Company’) received a letter from the staff (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market, which continues to trade under the symbol ‘EYEN’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until December 30, 2024, to regain compliance with this requirement. To regain compliance, the closing bid price of the Company’s common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before December 30, 2024. If the Company does not regain compliance with Rule 5550(a)(2) by December 30, 2024, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other Nasdaq initial listing standards, except the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities will be subject to delisting. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing. The Company intends to actively monitor the minimum bid price of its common stock and may, as appropriate, consider available options to regain compliance. New Risk • Jun 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 67% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (67% increase in shares outstanding). Revenue is less than US$1m (US$8.8k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$21m net loss in 3 years). Market cap is less than US$100m (US$37.7m market cap). Major Estimate Revision • May 22
Consensus revenue estimates decrease by 32%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$5.23m to US$3.54m. EPS estimate increased from -US$0.693 to -US$0.68 per share. Pharmaceuticals industry in the US expected to see average net income growth of 3.3% next year. Consensus price target down from US$9.33 to US$9.00. Share price fell 30% to US$0.75 over the past week. Annuncio • May 16
Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024 Eyenovia, Inc. announced that they will report Q1, 2024 results After-Market on May 15, 2024 Annuncio • May 05
Eyenovia, Inc., Annual General Meeting, Jun 12, 2024 Eyenovia, Inc., Annual General Meeting, Jun 12, 2024, at 10:00 Eastern Daylight. Agenda: To elect the seven directors named in the accompanying proxy statement (the Proxy Statement") for one-year terms expiring in 2025 or until their successors have been elected and qualified; to ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the audit committee of the Company's Board of Directors; to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement; to indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of our named executive officers; and to discuss other matters. Annuncio • Apr 26
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension Eyenovia, Inc. provided an update on its two FDA-approved products. Phase IV study of Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% Eyenovia announced results from a Phase IV study of Mydcombi designed to characterize the lowest deliverable dose for mydriasis (pupil dilation). Mydcombi is the only FDA-approved fixed dose combination of tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5%, and the first FDA-approved product in the Optejet. Current mydriatic eye drops used during eye exams have several limitations, including potential cross-contamination, difficulty instilling in patients with limited mobility, and in some patients, tolerability and safety issues. Phenylephrine, in higher amounts, has been known to cause serious potential systemic cardiovascular side effects in older patients, particularly those with high blood pressure. This Phase IV study was designed to determine the efficacy and duration of effect of the lowest deliverable dose of Mydcombi for pupil dilation. Twenty-nine subjects were treated with a half dose of Mydcombi (8µL per eye) and evaluated at the end of 2023 at the State University of New York School of Optometry by Dr. Denise Pensyl, OD. Study highlights: At 30 minutes post dose, clinically relevant pupil dilation was achieved in approximately 67% of patients; By 60 minutes, that percentage increased to 86%; The majority of patients returned to a pupil size of less than 5mm between 3.5 and 6 hours post-instillation, with 93% reaching that point by 6 hours; Administering a lower 8 microliter volume was well tolerated with minimal adverse events reported. New Risk • Apr 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (US$3.8k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$25m net loss in 3 years). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (US$34.6m market cap). Major Estimate Revision • Mar 29
Consensus revenue estimates increase by 40% The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from US$3.73m to US$5.23m. Forecast losses expected to reduce from -US$0.717 to -US$0.693 per share. Pharmaceuticals industry in the US expected to see average net income decline 1.0% next year. Consensus price target down from US$10.67 to US$9.33. Share price fell 14% to US$0.99 over the past week. Major Estimate Revision • Mar 25
Consensus revenue estimates increase by 27% The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from US$2.93m to US$3.73m. Forecast losses expected to reduce from -US$0.912 to -US$0.717 per share. Pharmaceuticals industry in the US expected to see average net income decline 0.7% next year. Consensus price target of US$10.67 unchanged from last update. Share price fell 23% to US$1.18 over the past week. Major Estimate Revision • Mar 15
Consensus revenue estimates increase by 32% The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$430.0k to US$570.0k. EPS estimate unchanged from -US$0.68 at last update. Pharmaceuticals industry in the US expected to see average net income growth of 2.8% next year. Consensus price target of US$10.67 unchanged from last update. Share price was steady at US$1.59 over the past week. Annuncio • Mar 12
Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024 Eyenovia, Inc. announced that they will report Q4, 2023 results After-Market on Mar 18, 2024 Price Target Changed • Mar 08
Price target decreased by 8.6% to US$10.67 Down from US$11.67, the current price target is an average from 3 analysts. New target price is 575% above last closing price of US$1.58. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$0.68 next year compared to a net loss per share of US$0.83 last year. Major Estimate Revision • Mar 06
Consensus revenue estimates increase by 33% The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$420.0k to US$570.0k. EPS estimate unchanged from -US$0.67 at last update. Pharmaceuticals industry in the US expected to see average net income growth of 3.7% next year. Consensus price target of US$12.33 unchanged from last update. Share price fell 26% to US$1.70 over the past week. Major Estimate Revision • Mar 06
Consensus revenue estimates increase by 33% The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$420.0k to US$570.0k. EPS estimate unchanged from -US$0.67 at last update. Pharmaceuticals industry in the US expected to see average net income growth of 3.7% next year. Consensus price target of US$12.33 unchanged from last update. Share price fell 26% to US$1.70 over the past week. Major Estimate Revision • Jan 18
Consensus revenue estimates increase by 54% The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$550.0k to US$850.0k. EPS estimate unchanged at -US$0.665. Pharmaceuticals industry in the US expected to see average net income growth of 34% next year. Consensus price target of US$11.67 unchanged from last update. Share price fell 12% to US$1.59 over the past week. New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$27m free cash flow). Revenue is less than US$1m (US$1.2k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$70.2m market cap). Board Change • Dec 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Michael Geltzeiler was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annuncio • Nov 07
Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Eyenovia, Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023 Annuncio • Nov 03
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production Eyenovia, Inc. announced that the FDA has approved Eyenovia’s Supplemental New Drug Application (sNDA), adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis (office-based pupil dilation). Annuncio • Aug 08
Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Eyenovia, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023 Recent Insider Transactions • May 28
Insider recently bought US$234k worth of stock On the 25th of May, Stuart Grant bought around 88k shares on-market at roughly US$2.65 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$267k more in shares than they bought in the last 12 months. Annuncio • May 12
Eyenovia, Inc., Annual General Meeting, Jun 27, 2023 Eyenovia, Inc., Annual General Meeting, Jun 27, 2023, at 10:00 Eastern Daylight. Agenda: To elect the six directors named in the Proxy Statement for one-year terms expiring in 2024 or until their successors have been elected and qualified; to approve an amendment to the Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan to reserve an additional 1,000,000 shares of common stock for issuance thereunder; to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider and take action upon such other matters as may properly come before the meeting or any adjournment or postponement thereof. Annuncio • May 09
Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis Eyenovia, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first approved fixed dose combination of tropicamide and phenylephrine in the United States and also the first product using Eyenovia's proprietary Optejet device to be approved by any regulatory authority. Mydcombi is designed to improve the efficiency of the estimated 106 million office-based comprehensive eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. The product is contraindicated and should not be used in patients with known hypersensitivity to any component of the formulation. Annuncio • May 05
Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023 Eyenovia, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023 Recent Insider Transactions • May 03
Co-Founder recently sold US$300k worth of stock On the 27th of April, Tsontcho Ianchulev sold around 60k shares on-market at roughly US$5.00 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Tsontcho's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • May 01
Co-Founder notifies of intention to sell stock Tsontcho Ianchulev intends to sell 60k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$5.00, it would amount to US$300k. Since September 2022, Tsontcho's direct individual holding has decreased from 585.90k shares to 465.90k. Company insiders have collectively bought US$525k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Apr 16
Co-Founder notifies of intention to sell stock Tsontcho Ianchulev intends to sell 40k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of April. If the sale is conducted around the recent share price of US$4.00, it would amount to US$160k. Since June 2022, Tsontcho's direct individual holding has decreased from 585.90k shares to 505.90k. Company insiders have collectively bought US$676k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Apr 06
Co-Founder notifies of intention to sell stock Tsontcho Ianchulev intends to sell 40k shares in the next 90 days after lodging an Intent To Sell Form on the 31st of March. If the sale is conducted around the recent share price of US$3.50, it would amount to US$140k. Since June 2022, Tsontcho has owned 585.90k shares directly. Company insiders have collectively bought US$676k more than they sold, via options and on-market transactions, in the last 12 months. 
